Tecentriq shows promise in treating early-stage lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III IMpower010 trial reinforced the significant disease-free survival benefit offered by Tecentriq (atezolizumab) for people with stage II-IIIA non-small cell lung cancer whose tumors express PD-L1≥1%. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login